Sana Biotechnology Q2 Adj $(0.32) Misses $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Sana Biotechnology (NASDAQ:SANA) reported Q2 losses of $(0.32) per share, missing the analyst consensus estimate of $(0.28) by 14.29%. This represents a 28.89% improvement over the $(0.45) per share loss from the same period last year.
August 08, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sana Biotechnology reported Q2 losses of $(0.32) per share, missing the analyst consensus estimate of $(0.28) by 14.29%. Despite the miss, the losses are an improvement from the $(0.45) per share loss in the same period last year.
The miss on earnings estimates is likely to negatively impact the stock price in the short term. However, the improvement in losses compared to the same period last year may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100